Skip to main content

Table 1 Program characteristics of included articles (N = 25)

From: Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review

Article study design/type

N (%)

Commentary or program description

18 (72%)

Research with quantitative outcomes

4 (16%)

Research with qualitative outcomes

2 (8%)

Case report

1 (4%)

 Country

 United States

13 (52%)

 Puerto Rico

1 (4%)

 South Africa

1 (4%)

 United Kingdom

1 (4%)

 Ireland

1 (4%)

 India

2 (8%)

 Australia

3 (12%)

 Canada

1 (4%)

 Spain

1 (4%)

 Italy

1 (4%)

Care setting

 Substance use treatment

13 (52%)

 Outreach/harm reduction

7 (28%)

 Correctional facility

2 (8%)

 Mobile clinic

2 (8%)

 Primary care/general practitioner

1 (4%)

Type of organization

 Academic institution

7 (28%)

 Government/academic partnership

3 (12%)

 Government

4 (16%)

 Non-for-profit organization

3 (12%)

 Independent clinic

7 (28%)

 Commercial laboratory

1 (4%)

Services described

 OUD Treatment

21 (84%)

 Harm reduction

1 (4%)

 OUD Treatment and Harm reduction

3 (12%)

Types of medications offered

 Sublingual buprenorphine

16 (64%)

 Extended release buprenorphine

3 (12%)

 Methadone

11 (44%)

 Extended-release naltrexone

1 (4%)

 Naloxone

12 (48%)

New vs. modification of program

 New

4 (16%)

 Modification

21 (84%)